Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics ...Middle East

Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors Clinical data from AML...

Hence then, the article about coeptis therapeutics signs agreement to acquire allogeneic immuno oncology nk platform in phase 1 clinical trials from deverra therapeutics was published today ( Tuesday 18/04/2023 - 02:36 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics )

Also on site :

• This Guitarist Helped Shape One of the Most Iconic Sounds of the '90s
• 32 Years Ago Today, Iconic '90s Rocker Died at the Age of 27
• I Tried 19 Frozen Pizzas—And the Winner Is a New Find That Won by a Landslide